Abstract 837P
Background
DCBCLs constitute 40% of all NHLs globally. In Pakistan 76.4% of all NHLs to be diagnosed as DCBCLs. The standard of treatment given with the addition of rituximab to the previous combination chemotherapy (R-CHOP) showed better cure rates with decreased toxicity. However, one such combination DA-REPOCH showed promising results but studies conducted to compare the efficacy of R-CHOP with that of DA-REPOCH have not been conclusive. This study aims to compare the survival rates of the DA-REPOCH regimen with the R-CHOP regimen.
Methods
A prospective follow-up study was conducted with 113 patients to investigate the outcomes of treatment for the DLBCL at the Aga Khan University Hospital, Pakistan. All included patients were diagnosed with the DE/DH, or TE/TH subtype of DLBCL according to the WHO classification and were treated from January 1, 2019, to December 31, 2020, with either DA-REPOCH or R-CHOP. All reported toxicities were graded. PFS and OS were calculated in months using Kaplan-Meier survival curves. The cox-proportional hazard regression model was used to estimate the survival in patients receiving these treatment regimens.
Results
The survival rate in normal DLBCL patients receiving R-CHOP as the standard treatment was 81.8%, while the survival rate was 82.8% among double/triple expressor lymphoma patients receiving R-DA-EPOCH, and 83.3% among double/triple expressor lymphoma patients receiving R-CHOP. For double/triple expressor lymphoma patients, in those receiving R-DA-EPOCH, the PFS was 10.5 months and OS was 13.8 months, in those receiving R-CHOP, the PFS was 10.6 months and OS was 14.2 months.
Conclusions
The findings of our study demonstrated that the survival rate in both R-CHOP and R-DA-EPOCH is mostly similar. A multicenter study is required for comparison of treatment efficacy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.